<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877448</url>
  </required_header>
  <id_info>
    <org_study_id>BVX002</org_study_id>
    <nct_id>NCT00877448</nct_id>
  </id_info>
  <brief_title>A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)</brief_title>
  <official_title>A Phase I/II, Randomized, Single-Blind, Placebo-Controlled Escalating Double-Dose Safety Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BiondVax Pharmaceuticals ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BiondVax Pharmaceuticals ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety
      study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>day 0 until day 42 (termination visit)</time_frame>
    <description>Number of adverse events per cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related Adverse Events</measure>
    <time_frame>Day 0 until day 42 (termination visit)</time_frame>
    <description>Number of treatment-related adverse events per cohort</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Multimeric-001 250 Mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multimeric-001 250 Mcg in PBS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvanted Multimeric-001 250 Mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 Mcg in montanide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phosphate Buffered saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-adjuvanted placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvanted PBS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adjuvant was montanide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multimeric-001 500 Mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multimeric-001 in PBS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvanted Multimeric-001 500 Mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant was montanide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multimeric-001 125 Mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multimeric-001 in PBS</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted Multimeric-001 250 Mcg</intervention_name>
    <arm_group_label>Multimeric-001 250 Mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multimeric-001 250 Mcg</intervention_name>
    <arm_group_label>Adjuvanted Multimeric-001 250 Mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Phosphate Buffered saline</intervention_name>
    <arm_group_label>Phosphate Buffered saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted PBS</intervention_name>
    <arm_group_label>Adjuvanted PBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted Multimeric-001 500 Mcg</intervention_name>
    <arm_group_label>Adjuvanted Multimeric-001 500 Mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multimeric-001 500 Mcg</intervention_name>
    <arm_group_label>Multimeric-001 500 Mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multimeric-001 125 Mcg</intervention_name>
    <arm_group_label>Multimeric-001 125 Mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females between 18 and 55 years (inclusive) of age.

          -  Non-smoking (by declaration) for a period of at least 6 months.

          -  Subjects able to adhere to the visit schedule and protocol requirements and be
             available to complete the study.

          -  Haematology and Chemistry values within normal ranges or with no clinical significance

          -  Subjects who provide written informed consent to participate in the study

        Exclusion Criteria:

          -  Known history of significant medical disorder, which in the investigator's judgment
             contraindicates administration of the study medications.

          -  Ongoing flu symptoms or influenza

          -  Any clinically significant abnormality upon physical examination or in the clinical
             laboratory test at screening visit.

          -  Treatment with immune immunosuppressant drugs or other immune enhancing drugs.

          -  Subjects who have been immunized with anti-influenza vaccine or infected by influenza
             virus within one year prior to the screening visit.

          -  Administration of any vaccine 30 days before the screening visit.

          -  Known history of drug or alcohol abuse.

          -  Known history of HIV, hepatitis C or B virus (HCV or HBV)

          -  Subjects with known Guillain Barr√© Syndrome in the past

          -  2 or more hospitalization within the last year prior to screening visit

          -  Increased liver enzymes 2.5 times above the upper reference level

          -  Known hypersensitivity and/or allergy to any drugs

          -  Any acute medical situation (e.g. acute infection) within 48 hours of study start,
             which is considered of significance by the Principal Investigator.

          -  Subjects who participated in another clinical study within 30 days prior to study
             entry

          -  Subjects who are non-cooperative or unwilling to sign consent form.

          -  Pregnant or lactating women at entry to study and those that are unwilling to agree to
             continue precautions for two months after completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Atsmon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sourasky Medical Center, Tel Aviv, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tasmc Crc</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. J Clin Immunol. 2012 Jun;32(3):595-603. doi: 10.1007/s10875-011-9632-5. Epub 2012 Feb 9.</citation>
    <PMID>22318394</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <results_first_submitted>August 1, 2012</results_first_submitted>
  <results_first_submitted_qc>February 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2013</results_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INFLUENZA</keyword>
  <keyword>VACCINE</keyword>
  <keyword>UNIVERSAL</keyword>
  <keyword>SAFETY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was done on a running basis after eligibility of inclusion/exclusion criteria was met and subjects were invited to clinic after screening procedures within up to 21 days before their first vaccination.</recruitment_details>
      <pre_assignment_details>After meeting eligibility criteria to enter the study subjects were randomized simultaneously.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Multimeric-001 250 Mcg in PBS</title>
          <description>Multimeric - 001 250 mcg in Phosphate Buffered Solution (PBS) injected twice with the interval of 21 days between them.</description>
        </group>
        <group group_id="P2">
          <title>Adjuvanted Multimeric -001 250 Mcg</title>
          <description>Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total.</description>
        </group>
        <group group_id="P3">
          <title>PBS (Placebo)</title>
          <description>0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants.</description>
        </group>
        <group group_id="P4">
          <title>Adjuvanted PBS</title>
          <description>Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them.</description>
        </group>
        <group group_id="P5">
          <title>Multimeric-001 in PBS 500 Mcg</title>
          <description>Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days</description>
        </group>
        <group group_id="P6">
          <title>Adjuvanted Multimeric-001 500 Mcg</title>
          <description>Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days</description>
        </group>
        <group group_id="P7">
          <title>Multimeric-001 125 Mcg</title>
          <description>Multimeric-001 125 mcg in PBS administered once only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Multimeric-001 250 Mcg in PBS</title>
          <description>Multimeric - 001 250 mcg in Phosphate Buffered Solution injected twice with the interval of 21 days between them.</description>
        </group>
        <group group_id="B2">
          <title>Adjuvanted Multimeric -001 250 Mcg</title>
          <description>Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total.</description>
        </group>
        <group group_id="B3">
          <title>PBS (Placebo)</title>
          <description>0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants.</description>
        </group>
        <group group_id="B4">
          <title>Adjuvanted PBS</title>
          <description>Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them.</description>
        </group>
        <group group_id="B5">
          <title>Multimeric-001 in PBS 500 Mcg</title>
          <description>Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days</description>
        </group>
        <group group_id="B6">
          <title>Adjuvanted Multimeric-001 500 Mcg</title>
          <description>Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days</description>
        </group>
        <group group_id="B7">
          <title>Multimeric-001 125 Mcg</title>
          <description>Multimeric-001 125 mcg in PBS administered once only.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="4.0"/>
                    <measurement group_id="B2" value="25.8" spread="8.8"/>
                    <measurement group_id="B3" value="25.2" spread="5.3"/>
                    <measurement group_id="B4" value="26.0" spread="8.4"/>
                    <measurement group_id="B5" value="29.0" spread="7.4"/>
                    <measurement group_id="B6" value="25.2" spread="4.5"/>
                    <measurement group_id="B7" value="25.7" spread="3.3"/>
                    <measurement group_id="B8" value="25.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Number of adverse events per cohort</description>
        <time_frame>day 0 until day 42 (termination visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multimeric-001 250 Mcg in PBS</title>
            <description>Multimeric - 001 250 mcg in Phosphate Buffered Solution injected twice with the interval of 21 days between them.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Multimeric -001 250 Mcg</title>
            <description>Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total.</description>
          </group>
          <group group_id="O3">
            <title>PBS (Placebo)</title>
            <description>0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants.</description>
          </group>
          <group group_id="O4">
            <title>Adjuvanted PBS</title>
            <description>Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them.</description>
          </group>
          <group group_id="O5">
            <title>Multimeric-001 in PBS 500 Mcg</title>
            <description>Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days</description>
          </group>
          <group group_id="O6">
            <title>Adjuvanted Multimeric-001 500 Mcg</title>
            <description>Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days</description>
          </group>
          <group group_id="O7">
            <title>Multimeric-001 125 Mcg</title>
            <description>Multimeric-001 125 mcg in PBS administered once only.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of adverse events per cohort</description>
          <units>number of reported events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Adverse Events</title>
        <description>Number of treatment-related adverse events per cohort</description>
        <time_frame>Day 0 until day 42 (termination visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multimeric-001 250 Mcg in PBS</title>
            <description>Multimeric - 001 250 mcg in Phosphate Buffered Solution injected twice with the interval of 21 days between them.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Multimeric -001 250 Mcg</title>
            <description>Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total.</description>
          </group>
          <group group_id="O3">
            <title>PBS (Placebo)</title>
            <description>0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants.</description>
          </group>
          <group group_id="O4">
            <title>Adjuvanted PBS</title>
            <description>Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them.</description>
          </group>
          <group group_id="O5">
            <title>Multimeric-001 in PBS 500 Mcg</title>
            <description>Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days</description>
          </group>
          <group group_id="O6">
            <title>Adjuvanted Multimeric-001 500 Mcg</title>
            <description>Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days</description>
          </group>
          <group group_id="O7">
            <title>Multimeric-001 125 Mcg</title>
            <description>Multimeric-001 125 mcg in PBS administered once only.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Adverse Events</title>
          <description>Number of treatment-related adverse events per cohort</description>
          <units>number of reported events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>day 0 until day 42 (termination visit)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Multimeric-001 250 Mcg in PBS</title>
          <description>Multimeric - 001 250 mcg in Phosphate Buffered Solution injected twice with the interval of 21 days between them.</description>
        </group>
        <group group_id="E2">
          <title>Adjuvanted Multimeric -001 250 Mcg</title>
          <description>Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total.</description>
        </group>
        <group group_id="E3">
          <title>PBS (Placebo)</title>
          <description>0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants.</description>
        </group>
        <group group_id="E4">
          <title>Adjuvanted PBS</title>
          <description>Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them.</description>
        </group>
        <group group_id="E5">
          <title>Multimeric-001 in PBS 500 Mcg</title>
          <description>Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days</description>
        </group>
        <group group_id="E6">
          <title>Adjuvanted Multimeric-001 500 Mcg</title>
          <description>Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days</description>
        </group>
        <group group_id="E7">
          <title>Multimeric-001 125 Mcg</title>
          <description>Multimeric-001 125 mcg in PBS administered once only.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="10" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="11" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" events="6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="13" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" events="9" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E6" events="12" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculosceletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and Subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tamar Ben-Yedidia, PhD</name_or_title>
      <organization>BiondVax Pharmaceuticals Ltd.</organization>
      <phone>972-8-9302529</phone>
      <email>benyedidia@BiondVax.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

